Sie sehen das neue Design von cash. Details
Die klassische Ansicht finden Sie hier
Newron Pharmaceuticals Potential Takeover
Newron is developing five additional medicines, including three for rare diseases.
Given the sure bet with safinamide and the pipeline of drugs, a takeover by a mid-cap company that specializes in neurological diseases is possible, Devani said.
“It’s not unreasonable to assume that whoever licenses the drug is going to see the attraction of capturing more of safinamide’s value by acquiring Newron,” he said.
Weber declined to say whether any companies have approached Newron with a takeover offer.
Wikifolio: Stratos Investment
"No information is intended to be considered as advice and is not a solicitation to buy or sell"
© 1998-2016 / cash
| Impressum |